Novel inhibitor of the permeability transition pore (PTP)

Novel Potent and Selective VIPR2 Antagonist, Counteracting Cognitive Decline in a Mouse Model of Psychiatric Disorders

Novel highly selective β3-adrenoceptor agonist being developed for the treatment of diabetes and obesity

Highly potent and selective antagonist for the AMPA receptors, exhibiting good neuroprotective effects in vivo

Novel neutrophil elastase (NE) inhibitor, decreasing expression of TGF-ß Signal Related Genes

Topo II inhibitor, exhibiting cytotoxic effects against tumour cells

Potassium channel opener

Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c

Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity.

Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met

Novel stabilizer of the KRAS4b-PDEδ complex, decreasing the proliferation of colorectal cancer cells, and increasing apoptosis via decreased activation of oncogenic KRAS4b signaling

Novel specific inhibitor of oncogenic KRAS4b signaling, stabilizing the KRAS4b-PDEδ complex and remarkably decreasing tumor size and triggered apoptosis of tumor cells

Novel irreversible inhibitor of KRAS(G12C)

Novel KATP channel opener, exerting cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury

Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus

Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity

Novel potent antimicrotubule agent, exhibiting potent cytotoxicity against HT-29 cells by strongly binding to tubulin and inducing microtubule depolymn.

Novel selective, orally bioavailable, PAK4 allosteric modulator against triple negative breast cancer

Novel non-chain terminating nucleoside analog anti-HIV inhibitor

Natural anti-TNBC agent, significantly suppressing the triple-negative breast cancer (TNBC) tumor growth without causing side effects

Novel enhancer of cGMP activity; Aortic smooth muscle relaxant

Novel enhancer of cGMP activity; Aortic smooth muscle relaxant

Novel inhibitor of amyloid-β aggregation, ameliorating the neurodegenerative disorder

Novel inhibitor of amyloid-

Novel Potent and Selective EP4 Agonist

Novel Potent Hematopoietic Prostaglandin D2 Synthase (H-PGDS) Inhibitor

Novel BACE1 inhibitor with a non-acidic heterocycle at the P1' position

Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe

Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe

Selective S1P3 agonist